Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for dermatological disorders and other significant medical needs. The company focuses on conditions such as eczema, chronic wounds, psoriasis, asthma, and acne. Utilizing their proprietary BioLexa Platform, Hoth Therapeutics aims to create two topical cream products to treat eczema and reduce post-procedure infections in aesthetic dermatology patients.
Hoth Therapeutics has established numerous license and partnership agreements with prestigious institutions including The George Washington University, The University of Maryland Baltimore, Isoprene Pharmaceuticals, Inc., North Carolina State University, Chelexa Biosciences, Inc., The University of Cincinnati, and Zyla Therapeutics, Inc. Notably, Hoth is co-developing a topical treatment with Zyla Therapeutics for cutaneous lupus erythematosus, an autoimmune disease that severely impacts patient quality of life.
The company’s research collaborations extend to various areas including HT-001, a potential treatment for cancer patients experiencing skin toxicities from Epidermal Growth Factor Receptor Inhibitors (EGFRI). Hoth has recently received FDA clearance to proceed with protocol amendments in its ongoing Phase 2a clinical trials for HT-001, aiming to optimize clinical outcomes.
Hoth Therapeutics has also made strides in Alzheimer's Disease research with its HT-ALZ project, targeting neuroinflammation and cognitive deficits by antagonizing the NK1 receptor. Pre-clinical research has shown promising results in improving cognitive functions among Alzheimer's patients.
In addition to their pipeline, Hoth's subsidiary Merveille.ai has been pivotal in advancing obesity treatment using artificial intelligence. The discovery of a promising new therapeutic candidate for obesity, leveraging large language model technologies, underscores their commitment to innovative health solutions.
Financially, Hoth Therapeutics recently engaged in an agreement to exercise warrants, raising approximately $4.2 million to support its working capital needs. Their strategic partnership with Venable, LLP further strengthens their intellectual property protection, vital for ongoing and future therapeutic developments.
Collaborations with Wise Systems International SRL and integration of the Nvidia BioNeMo AI platform are set to enhance Hoth's drug discovery capabilities, leveraging artificial intelligence for cutting-edge therapeutic advancements.
Hoth Therapeutics, Inc. (Nasdaq: HOTH) received a 180-day extension from Nasdaq to comply with the $1.00 minimum bid price requirement, giving the company until December 26, 2022, to regain compliance. This decision follows an earlier notification from Nasdaq regarding Hoth's non-compliance based on its stock performance over the previous 30 days. If the company achieves the bid price requirement for 10 consecutive business days during this period, Nasdaq will confirm compliance. Failure to do so may lead to potential delisting, though the company can appeal such a decision.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that it has received approval from the Bellberry Human Research Ethics Committee in Australia to proceed with the next phase of its BioLexa trial for Atopic Dermatitis patients. This approval marks a significant milestone in Hoth's clinical trial journey. BioLexa is a patented antimicrobial topical formulation designed to prevent Staphylococcal biofilm formation, which is critical for treating chronic infections that can lead to antibiotic resistance. The company aims to leverage this opportunity to enhance patient quality of life through innovative therapies.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced that its Annual Meeting of Shareholders, originally scheduled for June 15, 2022, has been adjourned until June 23, 2022, at 12:00 p.m. ET. This decision aims to allow additional time for proxy solicitation and to achieve a quorum for voting. The meeting will be conducted virtually. Shareholders of record as of April 25, 2022, are encouraged to vote their shares by 11:59 p.m. ET on June 22, 2022. No changes to the proposals for the meeting have been made.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced an extension of its Sponsored Research Agreement with Washington University in St. Louis to further investigate HT-ALZ, a potential treatment for Alzheimer's disease. The ongoing research aims to establish a human equivalent dose for HT-ALZ, based on previous studies showing its ability to reduce amyloid β (Aβ) levels in mouse models. The study is led by Dr. Carla Yuede and Dr. John Cirrito, focusing on the effects of chronic administration on cognitive outcomes in Alzheimer’s models.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced preliminary findings from its Phase 1b clinical trial of BioLexa Lotion for mild to moderate atopic dermatitis. Conducted in Australia, the study showed some patients experienced improvement in symptoms across three efficacy endpoints: Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), and Investigator Global Assessment (IGA). No adverse events were reported during the dosing period. Full study results will be released later.
Hoth Therapeutics has introduced HT-TBI, a novel drug-device combination aimed at treating secondary brain injury related to ischemic strokes and traumatic brain injuries. This product offers point-of-care treatment options for patients and emergency responders, addressing significant delays in delivering care, which can worsen patient outcomes. Statistics reveal over 12.2 million new strokes occur annually, underscoring the urgency of timely intervention. HT-TBI represents Hoth's commitment to improving neurological health through innovative solutions.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) has successfully closed an underwritten public offering of 8,235,294 shares of common stock at a price of $0.85 per share, generating approximately $7.0 million in gross proceeds. The offering included a 45-day option for underwriters to purchase an additional 1,235,294 shares. Proceeds will be allocated for general corporate and working capital purposes. The offering was conducted under a shelf registration statement filed with the SEC.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced its acceptance to present preclinical data for HT-ALZ, intended for Alzheimer's treatment, at the Alzheimer's Association International Conference scheduled for July 31 – August 4, 2022, in San Diego, California. Lead researcher Dr. Carla Yuede will present findings from cognitive and behavioral studies using an APP/PS1 mouse model. Hoth focuses on developing therapies for unmet medical needs, including Alzheimer's disease and other conditions.
Hoth Therapeutics (NASDAQ: HOTH) announced the pricing of an underwritten public offering of 8,235,294 shares of common stock at $0.85 per share, aiming for gross proceeds of approximately $7.0 million. The offering will close on or about April 14, 2022, subject to customary conditions. The funds will be used for general corporate and working capital purposes. EF Hutton is acting as the sole book-running manager. The offering falls under a 'shelf' registration statement declared effective on March 11, 2020.
Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced an underwritten public offering of common stock, managed by EF Hutton. The offering is made under a 'shelf' registration statement effective since March 11, 2020. It aims to gather funds to support Hoth's development of innovative therapies targeting unmet medical needs in various health areas, including skin toxicities and Alzheimer’s Disease. A prospectus supplement will provide additional details and will be filed with the SEC.
FAQ
What is the current stock price of Hoth Therapeutics (HOTH)?
What is the market cap of Hoth Therapeutics (HOTH)?
What is Hoth Therapeutics, Inc.?
What conditions does Hoth Therapeutics focus on?
What is the BioLexa Platform?
Who are some of Hoth Therapeutics' partners?
What is HT-001?
What recent advancements have been made in Alzheimer's Disease research by Hoth Therapeutics?
How is Hoth Therapeutics advancing obesity treatment?
What financial actions has Hoth Therapeutics recently taken?
What is the significance of Hoth Therapeutics' partnership with Venable, LLP?
How is artificial intelligence being used by Hoth Therapeutics?
